EDWIN CROSIER: Open Payments
NPI 1447559752 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,058 in 102 payments from 26 companies in 2025. Trend: 2023 $0 · 2024 $1,614 · 2025 $2,058
Food & beverage: $2,058
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 17 | $358 |
| Dexcom, Inc. | 20 | $213 |
| Lilly USA, LLC | 12 | $165 |
| Sequel Med Tech, LLC | 2 | $162 |
| SANOFI-AVENTIS U.S. LLC | 2 | $109 |
| Madrigal Pharmaceuticals | 5 | $104 |
| Xeris Pharmaceuticals, Inc. | 4 | $84 |
| Novartis Pharmaceuticals Corporation | 4 | $84 |
| Globus Medical, Inc. | 2 | $78 |
| Corcept Therapeutics | 3 | $62 |
Products named: Ozempic, Dexcom G6 Transmitter, TWIIST, MOUNJARO, TZIELD, REZDIFFRA, LEQVIO, Senza.
Industry payments across MO — which companies pay providers there.
